Trial Profile
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liposarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms SU2C-SARC032
- 15 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 12 May 2023 Planned End Date changed from 30 Jul 2025 to 1 Sep 2028.
- 12 May 2023 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2025.